The present invention relates generally to systems for providing supplemental oxygen to patients and, more particularly, to oxygen conserving devices for such systems.
Respiratory diseases, such as bronchitis and emphysema, cause patients to suffer from deterioration of lung function. Health care providers often prescribe supplemental oxygen to such patients so that they can inhale the supplemental oxygen along with ambient atmospheric air in order to maintain a sufficient oxygen concentration level in the blood stream. The supplemental oxygen is provided by a system that stores or generates the oxygen and provides it to the patient via a nasal cannula.
In early supplemental oxygen delivery systems, oxygen was delivered on a continuous flow basis, albeit at a low, fixed flow rate, throughout the entire breathing cycle to the nose of the patient by a tube which interconnected a source of oxygen with a nasal cannula. Although such systems were effective, oxygen was lost to the ambient atmosphere since the continuous flow of oxygen was provided to the patient's nose regardless if the patient was inhaling or exhaling.
In response to the waste of oxygen associated with the earlier prior art supplemental oxygen delivery systems, more efficient prior art systems and devices were developed and implemented for delivery of supplemental oxygen to patients. These devices included oxygen conserving features. Such devices include those which provide oxygen “on demand” to the patient. “On demand” systems deliver oxygen to the patient after the beginning of the inhalation interval of the breathing cycle while no oxygen is delivered to the patient during any portion of the exhalation interval of the breathing cycle.
Examples of such prior art supplemental oxygen delivery devices are presented in U.S. Pat. Nos. 4,462,398 and 4,519,387, both to Durkan et al. In the device of these patents, a control circuit responsive to a sensor operates a valve to supply pulses of oxygen through a cannula to a patient when negative pressure indicating the initial stage of inhalation is detected by the sensor. The sensor may be a pressure-to-electric switch/pressure transducer. The pulse of gas delivered to the patient can have a preselected pulse profile.
U.S. Pat. No. 4,686,975 to Naimon et al. also discloses a supplemental respiratory device wherein small pressure changes within an airway are monitored so that gas is only supplied during patient inhalation. The nasal cannula leads from the airway to the sensing means which takes the form of a pressure transducer.
In the devices of the above patents, and other similar prior art devices and systems, it is advantageous to apply a commercially available pressure transducer. Such transducers are available from Honeywell Inc. of Morristown, N.J. (Micro Switch model 24 PC), Sensym of Milpitas, Calif. (model SX) and other manufacturers. Such pressure transducers are readily available, inexpensive, small and reliable.
In order to reliably identify the onset of patient inhalation, the pressure transducer must sense a pressure in the cannula of approximately −0.1 cm of water at atmospheric pressure. Pressure transducers have an associated drift due to time, temperature and applied pressure (hysteresis). As a result, to achieve the necessary pressure sensitivity, the pressure transducer must be accurately calibrated or zeroed at atmospheric pressure. The pressure transducers of the above paragraph, however, do not feature a built in reference to atmospheric pressure. Accordingly, the problem exists as to how to efficiently calibrate or zero the pressure transducer of an “on demand” supplemental oxygen delivery device.
Some prior art supplemental oxygen delivery devices, such as the Pulsair/DeVilbiss OMS 20, have an adjustable pressure transducer by which the set triggering point may be manually adjusted. The set triggering point is the pressure at which the device is triggered to deliver oxygen. Such devices, however, require periodic adjustment to assure consistent triggering without “auto-cycling.” Auto-cycling occurs when the set trigger point is at or above atmospheric pressure.
Other prior art supplemental oxygen delivery devices, such as the AirSep Impulse Select, monitor an airway for a change in pressure instead of an absolute pressure level. This approach, however, carries with it the disadvantage that under some breathing conditions, the device might interpret a strong exhalation (decreasing expiratory flow) as the same as an inspiration (increasing inspiratory flow) as the slopes of the pressure profile waveforms for each are similar. As a result, the device may be triggered to deliver oxygen at an inappropriate time.
The pressure transducer of a supplemental oxygen delivery device may also be calibrated to an assumed atmospheric pressure when the device is powered on, as in the case of the DeVilbiss EX2000 device. Such an approach, however, may result in an incorrect reference pressure if the patient is breathing on the cannula when the device is turned on. An incorrect reference pressure causes the device to be difficult to trigger or the device may trigger, and thus deliver oxygen, at the wrong time.
Finally, prior art supplemental oxygen delivery devices such as the Transtracheal Systems DOC2000, DOC3000 and DeVilibiss EX2005 feature two valves. The first valve controls the delivery of oxygen to the patient. The second valve is used to vent the pressure transducer to atmospheric pressure while oxygen is being delivered to the patient. This allows the pressure transducer to be calibrated or zeroed to atmospheric pressure. While this approach is reliable, it has a high associated cost and power consumption because two valves are required.
Accordingly, it is an object of the present invention to provide a self-calibrating supplemental oxygen delivery system;
It is another object of the present invention to provide a supplemental oxygen delivery system that is reliable;
It is another object of the present invention to provide an “on demand” supplemental oxygen delivery system;
It is another object of the present invention to provide a supplemental oxygen delivery system that is cost effective to construct;
It is still another object of the present invention to provide a supplemental oxygen delivery system that is economical to operate.
The present invention is directed to a system for delivering supplemental oxygen, or other gases, to a patient. The system includes a tank containing oxygen and a nasal cannula through which oxygen gas from the tank may be provided to the patient. The system also includes a pressure transducer and a transducer line in communication with the pressure transducer. The transducer line is provided with an orifice. A 3-port two position solenoid valve is in communication with the nasal cannula and is adjustable between an open condition where the tank is in communication with the nasal cannula and a closed condition where the pressure transducer is in communication with the nasal cannula via the transducer line.
A controller is in communication with the pressure transducer and the valve. The pressure transducer senses atmospheric pressure in the transducer line due to the orifice when the valve is in the open condition and the sensed pressure is stored and used by the controller as a reference pressure. The valve is configured in the open condition by the controller when the pressure in the nasal cannula, as sensed by the pressure transducer when the valve is in the closed condition, drops below the reference pressure, such as when a patient inhales.
The following detailed description of embodiments of the invention, taken in conjunction with the appended claims and accompanying drawings, provide a more complete understanding of the nature and scope of the invention.
An embodiment of the supplemental oxygen delivery system of the invention is indicated in general at 10 in
As illustrated in
The outlet port 18 of valve 12 communicates via line 24 with a nasal cannula 26 connected to a patient (not shown). While a single hose nasal cannula is illustrated in
Inlet port 16 of valve 12 communicates via transducer line 28 with a pressure transducer 32. As described earlier, suitable pressure transducers are available from Honeywell Inc. of Morristown, N.J. (Micro Switch model 24 PC), Sensym of Milpitas, Calif. (model SX) and other manufacturers. An orifice 34 is formed in the transducer line 28. An electronic control system or controller 36 controls the configuration of valve 12 via electrical lead 38 based upon the information received from the pressure transducer 32 via electrical lead 42. The controller or control system may take the form of a microcomputer, microprocessor or other programmable electronic device.
As illustrated in
Importantly, the orifice 34 is sized sufficiently small so as not to interfere with the operation of the transducer 32 in detecting the pressure drop at the commencement of patient inhalation when the valve is closed. However, the orifice is sufficiently large to allow the transducer line 28 to return to atmospheric pressure during patient inhalation when the valve is open. Testing has shown that an orifice of approximately 0.010 inches in diameter works well. The orifice may be formed in the transducer line 28 directly. Alternatively, a “tee” fitting, or some other component, such as a metal tube, 34 having the orifice formed therein may be inserted in series within transducer line 28.
A sample and hold circuit 44 is included within the control system 36 to “read” the value of the pressure transducer 32 and save it for future reference. More specifically, as will be explained in greater detail below with reference to
The newly-generated reference pressure is compared by the control system to the pressure detected by the pressure transducer in cannula 26 when the valve 12 is closed. The control system 36 opens valve 12 when the pressure detected within the cannula drops to some level below the reference pressure. As a result, the pressure transducer and control system are effectively calibrated or zeroed to atmospheric pressure.
The control system 36 features a timer 46 so that valve 12, once opened, remains opened for a predetermined period of time. When the time period expires, the control system automatically closes valve 12 so that port 14 is once again closed and port 16 is once again open. As such, the system is configured once again so that pressure transducer 32 may sense when the patient inhales.
A breathing cycle is graphed in FIG. 2 and is useful to illustrate the operation of the system of
The breathing cycle commences when the patient begins to inhale and terminates when a patient finishes exhaling. As a result, a breathing cycle consists of an inhalation interval and an exhalation interval. With reference to
The valve 12 of
The processing performed by the control system 36 of
As illustrated at 76 in
As illustrated at 78, the control system then configures the valve to the closed condition, illustrated in
With reference to
Power for the system may be provided by batteries 94 so that the system of
The supplemental oxygen delivery system of the present invention thus provides “on demand” delivery of oxygen to the patient and is self-calibrating so as to operate in a reliable and efficient fashion. The system is also economical to construct, maintain and operate as it does not require a second valve to perform the calibration. The omission of the second valve decreases construction and maintenance costs and increases battery life.
While the preferred embodiments of the invention have been shown and described, it will be apparent to those skilled in the art that changes and modifications may be made therein without departing from the spirit of the invention, the scope of which is defined by the appended claims.
This application claims priority from U.S. Provisional Patent Application Ser. No. 60/335,428, filed Oct. 19, 2001 now abandoned.
Number | Name | Date | Kind |
---|---|---|---|
4054133 | Myers | Oct 1977 | A |
4278110 | Price et al. | Jul 1981 | A |
4457303 | Durkan | Jul 1984 | A |
4462398 | Durkan et al. | Jul 1984 | A |
4484578 | Durkan | Nov 1984 | A |
4519387 | Durkan et al. | May 1985 | A |
4686975 | Naimon et al. | Aug 1987 | A |
4706664 | Snook et al. | Nov 1987 | A |
4827922 | Champain et al. | May 1989 | A |
4848332 | Champain | Jul 1989 | A |
4932402 | Snook et al. | Jun 1990 | A |
4971049 | Rotariu et al. | Nov 1990 | A |
5099836 | Rowland et al. | Mar 1992 | A |
5443062 | Hayes | Aug 1995 | A |
5551419 | Froehlich et al. | Sep 1996 | A |
5603315 | Sasso, Jr. | Feb 1997 | A |
5701883 | Hete et al. | Dec 1997 | A |
5720276 | Kobatake et al. | Feb 1998 | A |
5735268 | Chua et al. | Apr 1998 | A |
5839434 | Enterline | Nov 1998 | A |
5865174 | Kloeppel | Feb 1999 | A |
5881722 | DeVries et al. | Mar 1999 | A |
6000396 | Melker et al. | Dec 1999 | A |
6017315 | Starr et al. | Jan 2000 | A |
6131571 | Lampotang et al. | Oct 2000 | A |
6164276 | Bathe et al. | Dec 2000 | A |
6192884 | Vann et al. | Feb 2001 | B1 |
6224560 | Gazula et al. | May 2001 | B1 |
6237592 | Surjadi et al. | May 2001 | B1 |
6378520 | Davenport | Apr 2002 | B1 |
6526971 | Kellon | Mar 2003 | B2 |
6539940 | Zdrojkowski et al. | Apr 2003 | B2 |
6575164 | Jaffe et al. | Jun 2003 | B1 |
6668828 | Figley et al. | Dec 2003 | B1 |
Number | Date | Country | |
---|---|---|---|
20030150455 A1 | Aug 2003 | US |
Number | Date | Country | |
---|---|---|---|
60335428 | Oct 2001 | US |